替妥木单抗治疗甲状腺眼病的系统评价与荟萃分析
结果显示,替妥木单抗在随机对照试验和真实世界研究中均改善突眼和复视,但高血糖和听力损伤风险增加,提示需注意患者选择与监测。
要点
- 替妥木单抗在随机对照试验和真实世界研究中均改善突眼和复视。
- 真实世界研究中高血糖发生率为17%,听力损伤发生率为18%。
- 随机对照试验显示高血糖和听力损伤风险显著高于对照。
核心结论
- 替妥木单抗在不同研究设计中均改善突眼和复视,但真实世界实践中高血糖和听力损伤需引起重视。
研究设计与样本
- 系统评价与荟萃分析纳入6项随机对照试验和30项真实世界研究,评估静脉替妥木单抗治疗成人甲状腺眼病。
- 检索PubMed、Embase、Web of Science和Cochrane Library自建库至2026年8月10日,两名评价者独立筛选、提取数据并评估偏倚风险。
- 采用固定或随机效应模型,二分类结局用风险比(RR),连续结局用均数差,单臂真实世界研究用比例,GRADE评估证据确定性。
主要发现
- 随机对照试验中替妥木单抗组突眼缓解优于对照(RR 4.55,95%CI 2.52-8.23)。
- 真实世界研究中82%患者达到突眼缓解(95%CI 0.78-0.86;11项研究,482例患者)。
- 随机对照试验中替妥木单抗组复视缓解优于对照(RR 2.13,95%CI 1.51-2.98)。
- 真实世界研究中60%患者复视改善(95%CI 0.51-0.68;6项研究,204例患者)。
- 随机对照试验中替妥木单抗组高血糖(RR 2.67,95%CI 1.04-6.85)和听力损伤(RR 4.05,95%CI 1.50-10.96)风险增加。
关键数值与推荐
- 随机对照试验中替妥木单抗组突眼缓解RR为4.55(95%CI 2.52-8.23)。
- 随机对照试验中替妥木单抗组复视缓解RR为2.13(95%CI 1.51-2.98)。
- 随机对照试验中替妥木单抗组高血糖RR为2.67(95%CI 1.04-6.85),听力损伤RR为4.05(95%CI 1.50-10.96)。
- 真实世界研究中突眼缓解率82%(95%CI 0.78-0.86),复视改善率60%(95%CI 0.51-0.68),高血糖发生率17%(13项研究,671例患者),听力损伤发生率18%(13项研究,592例患者)。
临床怎么用
- 替妥木单抗可改善甲状腺眼病患者的突眼和复视,但需在治疗前评估高血糖和听力损伤风险并加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: Teprotumumab is the first FDA-approved biologic for moderate-to-severe thyroid eye disease (TED). Although efficacy has been established in randomized controlled trials (RCTs), real-world studies (RWS) have reported different efficacy and safety patterns, supporting an updated synthesis. CLINICAL RELEVANCE: A comprehensive assessment of teprotumumab across trials and routine clinical practice is needed to guide treatment decisions. METHODS: This systematic review and meta-analysis included RCTs and RWS evaluating intravenous teprotumumab in adults with TED and reporting at least one prespecified efficacy or safety outcome. Other anti-IGF-1R RCTs were used only in supplementary class analyses. PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to August 10, 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane RoB 2 tool and Joanna Briggs Institute criteria. Fixed- or random-effects models were selected according to heterogeneity. Risk ratios (RRs) were used for dichotomous outcomes, mean differences for continuous outcomes, and proportions for single-arm RWS. Certainty was evaluated using GRADE. The protocol was registered in PROSPERO (CRD420251152338). RESULTS: Thirty-six studies (6 RCTs and 30 RWS) were included; 4 RCTs evaluated teprotumumab and 2 evaluated other anti-IGF-1R antibodies. Proptosis response favored teprotumumab in RCTs (RR, 4.55; 95% confidence interval [CI], 2.52-8.23) and was achieved by 82% of patients in RWS (95% CI, 0.78-0.86; 11 studies, 482 patients). Diplopia response also favored teprotumumab in RCTs (RR, 2.13; 95% CI, 1.51-2.98), while 60% of patients improved in RWS (95% CI, 0.51-0.68; 6 studies, 204 patients). Hyperglycemia was more frequent with teprotumumab in RCTs (RR, 2.67; 95% CI, 1.04-6.85) and occurred in 17% of patients in RWS (13 studies, 671 patients). Hearing impairment was also increased in RCTs (RR, 4.05; 95% CI, 1.50-10.96) and occurred in 18% of patients in RWS (13 studies, 592 patients). CONCLUSION: Teprotumumab improves proptosis and diplopia across study designs, but hyperglycemia and hearing impairment in real-world practice warrant appropriate patient selection and monitoring.
引用
- Sun A, Wang X, Wang J, et al. Teprotumumab for Thyroid Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Real-World Studies. Am J Ophthalmol. 2026. PMID: 42810657. doi:10.1016/j.ajo.2026.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。